Self-administration of epoetin beta by peritoneal dialysis patients.

S. York, R. Kinney, T. E. Taber

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Recombinant human erythropoietin (epoetin) reverses the anemia of end stage renal disease. Benefits have been evaluated primarily in hemodialysis patients because of the ease of administration via existing intravenous access. Studies are under way to evaluate the feasibility of subcutaneous self-administration of epoetin in continuous ambulatory peritoneal dialysis (CAPD) patients. Preliminary study results, using the maintenance of target hemoglobin levels to measure success and a case study demonstrate the practicality of subcutaneous self-administration of epoetin in CAPD patients.

Original languageEnglish (US)
Pages (from-to)549-552
Number of pages4
JournalANNA journal / American Nephrology Nurses" Association
Volume18
Issue number6
StatePublished - Dec 1 1991
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Self-administration of epoetin beta by peritoneal dialysis patients.'. Together they form a unique fingerprint.

  • Cite this